Entering text into the input field will update the search result below

Antares Pharma Non-GAAP EPS of $0.02 beats by $0.01, revenue of $48.73M beats by $1.54M

Mar. 03, 2022 7:01 AM ETHalozyme Therapeutics, Inc. (HALO) StockBy: Gaurav Batavia, SA News Editor1 Comment
  • Antares Pharma press release (NASDAQ:ATRS): Q4 Non-GAAP EPS of $0.02 beats by $0.01.
  • Revenue of $48.73M (+10.5% Y/Y) beats by $1.54M.
  • The Company today provided its full-year 2022 revenue guidance range of $200 to $220 million, which does not include any unapproved products

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

nice numbers, hopefully we get some positive price increases...

Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, “The many accomplishments we achieved throughout the year contributed to our strong annual revenue growth of 23% to $184 million and increased adjusted EBITDA to almost $40 million for the full year. In 2021, our commercial team continued to build and maintain strong physician relationships that helped drive the 34% annual revenue increase in our flagship proprietary asset XYOSTED. We also worked relentlessly supplying devices for the strong demand of Teva’s generic EpiPen, which contributed approximately $70 million in annual revenue. Despite consistent challenges due to the pandemic, we successfully executed on our strategic initiatives and believe we have positioned the Company for continued growth.”

About HALO

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Halozyme Therapeutics, Inc.
Vaxcyte, Inc.
CRISPR Therapeutics AG
BridgeBio Pharma, Inc.
Immunovant, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.